Literature DB >> 19151118

Complementary or alternative therapy use and health status in systemic lupus erythematosus.

J Alvarez-Nemegyei1, A Bautista-Botello.   

Abstract

Despite their unproven efficacy and safety concerns, complementary and alternative therapies (CAT) are used by a high proportion of patients with systemic lupus erythematosus (SLE). A prospective survey of past and present CAT use was done on 192 patients (36.5 +/- 12.7 years; 106 +/- 85 months of disease duration; 94% women) with an SLE diagnosis according to ACR criteria. Quality of life [Short Form 36 (SF-36)] and cumulated damage (SLICC/ACR) were compared between CAT users and non-users. In all, 103 (53.6%; 95% CI: 46.8-60.9) patients were CAT users (median: two remedies/patient): two (1%) in the alternative mode (CAT instead of allopathic treatment); 101 (52.6%) in the complementary mode (CAT in addition to allopathic treatment). A univariate analysis showed CAT users to have higher cumulated damage (P = 0.01) levels, as well as lower physical function (P = 0.05), social function (P = 0.05) and bodily pain (P = 0.02) domain scores in the SF-36 survey. After adjustment for disease duration with a linear model, only differences in bodily pain (P = 0.04) and cumulated damage (P = 0.05) remained statistically significant. CAT use is apparently associated with lower health status in patients with SLE from Yucatan, Mexico. Because the study was cross-sectional, more research is needed to define the directionality of this association.

Entities:  

Mesh:

Year:  2009        PMID: 19151118     DOI: 10.1177/0961203308095946

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

Review 1.  Updated review of complementary and alternative medicine treatments for systemic lupus erythematosus.

Authors:  Carol M Greco; Claire Nakajima; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

2.  Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials.

Authors:  Ying Wang; Mei Han; Christopher E Pedigo; Zhi-Min Xie; Wei-Jie Wang; Jian-Ping Liu
Journal:  Chin J Integr Med       Date:  2021-07-28       Impact factor: 1.978

3.  Factors associated with the use of complementary therapies in Taiwanese patients with systemic lupus erythematosus: a cross-sectional study.

Authors:  Ming-Chi Lu; Hui-Chin Lo; Hsiu-Hua Chang; Chia-Wen Hsu; Malcolm Koo
Journal:  BMC Complement Med Ther       Date:  2021-10-01

Review 4.  Mechanistic Paradigms of Natural Plant Metabolites as Remedial Candidates for Systemic Lupus Erythromatosus.

Authors:  Acharya Balkrishna; Pallavi Thakur; Shivam Singh; Swami Narsingh Chandra Dev; Anurag Varshney
Journal:  Cells       Date:  2020-04-22       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.